December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Rejection of Conjunctival Tumors Using Pro-Inflammatory Signals
Author Affiliations & Notes
  • MP Hatton
    Ophthalmology Mass Eye and Ear Boston MA
  • MS Gregory
    Schepens Eye Research Institute Boston MA
  • VL Perez
    Ophthalmology Mass Eye and Ear Boston MA
  • BR Ksander
    Schepens Eye Research Institute Boston MA
  • Footnotes
    Commercial Relationships   M.P. Hatton, None; M.S. Gregory, None; V.L. Perez, None; B.R. Ksander, None. Grant Identification: NIH Grant EY09294
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1114. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MP Hatton, MS Gregory, VL Perez, BR Ksander; Rejection of Conjunctival Tumors Using Pro-Inflammatory Signals . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1114.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:Conjunctival tumors grow within a non-immune privileged ocular site. For this reason, we hypothesize these tumors are highly susceptible to anti-tumor inflammatory responses. In the present series of experiments we attempted to stimulate innate immunity, specifically neutrophils, to eliminate conjunctival tumors. Methods:Lymphoma cells were transfected with cDNA encoding for membrane FasL (mFasL), wild-type FasL (wtFasL), or no FasL. Clones of mFasL tumor cells that expressed low and high levels of mFasL were isolated using limiting dilution techniques. Tumors were injected into the subconjunctival space of syngeneic DBA/2 mice. Tumor growth and survival were recorded. Results:Tumors that express mFasL are capable of directly stimulating neutrophils to de-granulate. To determine if this pro-inflammatory signal could be used to induce rejection of subconjunctival tumors, the following experiments were performed. Syngeneic tumors (FasL negative) grew progressively within the subconjunctival space of DBA/2 mice. By contrast, tumors expressing mFasL were rapidly rejected within the first three days after injection. Tumor rejection occurred regardless of whether high or low levels of mFasL were expressed. Moreover, tumor rejection was rapid, complete, and not associated with non-specific destruction of the surrounding normal conjunctival tissue. Conclusion:Conjunctival tumors grow within a non-immune privileged ocular site and therefore are more susceptible to innate inflammatory responses mediated by neutrophils. Our data imply that membrane FasL can be used to successfully active innate immunity to reject tumors in the conjunctiva.

Keywords: 610 tumors • 365 conjunctiva • 437 inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.